{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:46:39Z","timestamp":1752551199215,"version":"3.41.0"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","license":[{"start":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T00:00:00Z","timestamp":1749772800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,13]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Linperlisib is a highly selective small-molecule inhibitor of phosphatidylinositol-3-kinase delta for the treatment of relapsed\/refractory follicular lymphoma.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>The patient was a 64-year-old male with peripheral T-cell lymphoma and diabetes mellitus who experienced hyperglycemia, hyponatremia, facial palsy, and myalgia during linperlisib treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>Drug-induced high blood sugar and hyponatremia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Active management of hyperglycemia during hospitalization and hyponatremia was corrected with active symptomatic treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>During hospitalization, the patient\u2019s hyperglycemia and hyponatremia were effectively managed through active symptomatic treatment. However, following a reduction in the linperlisib dose, the patient developed recurrent hyperglycemia, hyponatremia, and new-onset myalgia. Consequently, the patient declined further linperlisib therapy and permanently discontinued the medication.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Clinicians should be aware of the risk of complications such as hyperglycemia and hyponatremia in patients with lymphoma and diabetes receiving linperlisib.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000042875","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:00:52Z","timestamp":1750215652000},"page":"e42875","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Linperlisib causing high blood sugar and hyponatremia, leading to facial nerve paralysis and muscle nerve damage: A rare case report"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8516-4505","authenticated-orcid":false,"given":"Yu-cai","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Affiliated Hospital of Putian University, Putian, Fujian Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-fei","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Medical Technology, Putian University, Putian, Fujian Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9738-2349","authenticated-orcid":false,"given":"Lin-lin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Putian University, Putian, Fujian Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250618","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/1078-0432.CCR-22-2939","article-title":"The oral PI3Kdelta inhibitor linperlisib for the treatment of relapsed and\/or refractory follicular lymphoma: a phase II, single-arm, open-label clinical trial.","volume":"29","author":"Wang","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"Suppl_1","key":"R2-20250618","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1182\/blood-2021-150215","article-title":"A phase Ib study of linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma.","volume":"138","author":"Jin","year":"2021","journal-title":"Blood"},{"issue":"Suppl_1","key":"R3-20250618","doi-asserted-by":"crossref","first-page":"9395","DOI":"10.1182\/blood-2022-162127","article-title":"A study of linperlisib in the treatment of patients with relapsed and\/or refractory peripheral T-cell lymphoma.","volume":"140","author":"Qiu","year":"2022","journal-title":"Blood"},{"key":"R4-20250618","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-021-01140-z","article-title":"Phase 1 clinical trial of the PI3Kdelta inhibitor YY-20394 in patients with B-cell hematological malignancies.","volume":"14","author":"Jiang","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"Suppl_10","key":"R5-20250618","doi-asserted-by":"crossref","first-page":"x21","DOI":"10.1093\/annonc\/mdz440","article-title":"Management of toxicity to isoform alpha-specific PI3K inhibitors.","volume":"30","author":"Nunnery","year":"2019","journal-title":"Ann Oncol"},{"key":"R6-20250618","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1158\/1078-0432.CCR-18-3160","article-title":"A phase II randomized study of neoadjuvant letrozole plus alpelisib for hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (NEO-ORB).","volume":"25","author":"Mayer","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R8-20250618","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/14737140.2017.1285702","article-title":"Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.","volume":"17","author":"Greenwell","year":"2017","journal-title":"Expert Rev Anticancer Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T03:00:54Z","timestamp":1750215654000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,13]]},"references-count":7,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042875","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,13]]}}}